HKEX: 1801
2026 Interim report
View original source (HKEXnews)
Earlier from Innovent Biologics
- Voluntary announcement - jaypirca (pirtobrutinib) approved in china for a new indication in chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll) across all lines of therapy
- Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
- Altruist Biologics' Suzhou Site Receives EMA GMP Certification, Enabling Product Commercialization for the European Market
- Innovent Announces 2026 Interim Results and Business Updates